These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37951571)

  • 21. Risk of Chronic Rhinosinusitis With Nasal Polyps in Endotypes of Dermatophagoides pteronyssinus-Induced Rhinitis.
    De Marchi S; Cecchin E; De Marchi SU; Iuri F; Sechi LA
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1506-1514.e2. PubMed ID: 35074602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
    Rivero A; Liang J
    Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
    Quint T; Dahm V; Ramazanova D; Arnoldner MA; Kurz H; Janik S; Brunner PM; Knerer-Schally B; Weninger W; Griss J; Ristl R; Schneider S; Bangert C
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):506-516.e6. PubMed ID: 34678497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis.
    Aldinger JP; Dobyns T; Lam K; Han JK
    Expert Opin Biol Ther; 2021 Sep; 21(9):1143-1149. PubMed ID: 34334061
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps.
    Zhu R; Owen R; Wilkins J; Schoemaker R; Tian X; Gautier A; She G; Vadhavkar S; Cheu M; Wong K; Omachi TA; Putnam WS; Quartino AL
    Pulm Pharmacol Ther; 2021 Dec; 71():102080. PubMed ID: 34592476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.
    Rosso C; De Corso E; Conti V; Nitro L; Saibene AM; Parazzini E; Rinaldo R; De Pascalis S; Arnone F; Centanni S; Montuori C; D'Auria LM; Felisati G; Pipolo C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3017-3023. PubMed ID: 38347197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
    Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
    Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
    J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
    Gevaert P; Calus L; Van Zele T; Blomme K; De Ruyck N; Bauters W; Hellings P; Brusselle G; De Bacquer D; van Cauwenberge P; Bachert C
    J Allergy Clin Immunol; 2013 Jan; 131(1):110-6.e1. PubMed ID: 23021878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced sinonasal levels of 1α-hydroxylase are associated with worse quality of life in chronic rhinosinusitis with nasal polyps.
    Schlosser RJ; Carroll WW; Soler ZM; Pasquini WN; Mulligan JK
    Int Forum Allergy Rhinol; 2016 Jan; 6(1):58-65. PubMed ID: 26575398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
    Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic Review.
    Rahavi-Ezabadi S; Zhou S; Lee SE; Ference E; Magit A; Leuin S; Mohamed K; Rezaei N; Patel VA
    Otolaryngol Head Neck Surg; 2024 Jul; 171(1):35-44. PubMed ID: 38488239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
    Chen S; Zhou A; Emmanuel B; Thomas K; Guiang H
    Curr Med Res Opin; 2020 Nov; 36(11):1897-1911. PubMed ID: 32847417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologics in Chronic Rhinosinusitis: Current and Emerging.
    Boyd JT; Khanwalkar AR
    Immunol Allergy Clin North Am; 2024 Nov; 44(4):657-671. PubMed ID: 39389716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
    Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
    J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.
    Humbert M; Bousquet J; Bachert C; Palomares O; Pfister P; Kottakis I; Jaumont X; Thomsen SF; Papadopoulos NG
    J Allergy Clin Immunol Pract; 2019; 7(5):1418-1429. PubMed ID: 30928481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
    Favier V; Daveau C; Carsuzaa F; Fieux M; Vandersteen C; Castillo L; Papon JF; de Gabory L; Saroul N; Verillaud B; Rumeau C; Jankowski R; Michel J; de Bonnecaze G; Lecanu JB; Coste A; Béquignon E; Malard O; Mortuaire G
    BMJ Open; 2024 May; 14(5):e083112. PubMed ID: 38749694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of omalizumab in an atopic young adult with asthma and eosinophilic chronic rhinosinusitis with nasal polyps.
    Fadda GL; Galizia A; Maugeri L; Canevari RF; Crosetti E; Cavallo G
    Eur Rev Med Pharmacol Sci; 2022 May; 26(9):3320-3324. PubMed ID: 35587084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.